PepEvolutionBPC-157 + KPV
Gut and anti-inflammatory blend pairing BPC-157 with a picomolar NF-κB inhibitor — logical stack, no blend trial.
Verdict — C · Emerging / Mixed
A logical pairing for gut healing and systemic inflammation — BPC-157's sourcing and safety are strong, and KPV's NF-κB mechanism is mechanistically compelling. KPV's thin human evidence is the primary drag. Verify both components by COA.
Overview
The BPC-157 + KPV blend combines the well-sourced recovery peptide BPC-157 with KPV, an alpha-MSH-derived tripeptide that is a picomolar NF-κB inhibitor with in-vitro gut-lining and anti-inflammatory activity. The combination is often marketed for gut healing and systemic inflammation. KPV's human data is limited; the blend evidence is entirely component-derived. Both components have clean safety profiles. No fixed-blend RCT exists.
PepScore Breakdown — the four axes
Evidence
35% weightHow strong is the published human science?
Sourcing & COA
30% weightOur moatCan a buyer obtain an independently-verified, high-purity version? — our proprietary layer.
Safety & Risk
25% weightWhat is the real-world harm potential?
Practicality
10% weightHow easy is it to actually run a verified version?
Sources & Citations
Every claim cites a primary source. Citations are machine-audited against NCBI — see methodology.
Educational only — not medical advice. PepScore is an educational research grade, not a prescription or dosing recommendation. Some vendor links are affiliate links — this never affects grades. Consult a licensed healthcare provider before using any compound.